Literature DB >> 34950218

Identifying asymptomatic cases during the mass COVID-19 vaccination campaign: insights and implications for policy makers.

Francesco Chirico1,2, Gabriella Nucera3, Olayinka Ilesanmi4,5, Aanuoluwapo Afolabi4, Michal Pruc6, Lukasz Szarpak7,8.   

Abstract

Entities:  

Keywords:  COVID-19; asymptomatic; coronavirus disease; diagnostic; super spreader; vaccination

Year:  2021        PMID: 34950218      PMCID: PMC8686840          DOI: 10.2217/fvl-2021-0243

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


× No keyword cloud information.
Asymptomatic COVID-19 infections have a substantial role in the spread of SARS-CoV-2. Although often overlooked, asymptomatic persons may be contagious and facilitate transmission of SARS-CoV-2 to healthy people. Asymptomatic COVID-19 cases can transmit SARS-CoV-2 to others, although it has been reported that these patients are responsible for fewer secondary infections than symptomatic cases [1]. According to Oran et al., asymptomatic cases account for 40–45% of SARS-CoV-2 infections and can transmit the virus to others for an extended period, probably longer than 14 days [2,3]. In the literature, there is evidence that the high viral load, rather than symptoms, might be the predominant driver of SARS-CoV-2 transmission [4]. Noteworthy is the fact that the viral load of asymptomatic COVID-19 cases is comparable to or higher than that of symptomatic cases [5,6]. Therefore, asymptomatology and high viremia can coexist and thus constitute a major risk factor for the transmission of COVID-19 infection. Asymptomatic people could be; therefore, be described as the main drivers of the ongoing COVID-19 pandemic because they do not manifest symptoms that could raise one’s index of suspicion regarding their COVID-19 status. Identifying asymptomatic cases as drivers of the COVID-19 pandemic during the mass COVID-19 vaccination campaign is relevant. This may influence the public health decision-making process by governments and policymakers, which should be drawn from evidence-based information. During the ongoing mass vaccination campaign against COVID-19, there is much debate among public health stakeholders about the duration of immunity conferred by the COVID-19 vaccine as well as the development of herd immunity subsequently after vaccination. Available COVID-19 vaccines are incredibly effective in preventing a progression of SARS-CoV-2 infection among people. The recent B.1.617.2 (Delta) variant of SARS-CoV-2 is however a ‘dangerous variant’, and much knowledge is yet to be unraveled about this variant. As events unfold, there exists the likelihood that the Delta variant of SARS-CoV-2 will spread across the population, with resulting dire consequences [7]. The Delta variant of SARS-CoV-2 was identified in India in late 2020 and has subsequently been detected in approximately 60 countries [8]. The Delta variant has a potentially higher rate of transmission compared with other SARS-CoV-2 variants [9]. In July 2021, 469 COVID-19 cases were identified among Massachusetts residents, of which 346 (74%) of these cases had been fully vaccinated. Testing identified the Delta variant in 90% of specimens from 133 patients [10]. Therefore, the US CDC confirmed that fully vaccinated persons could transmit SARS-CoV-2 if infected with the Delta strain despite the >90% protection against hospitalization and death guaranteed by mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna). Consequently, the CDC released an updated mask recommendation to ensure that vaccinated persons do not shun public health safety measures. This would help to avert instances in which SARS-CoV-2 gets transmitted to the unvaccinated or immunocompromised [11]. Indeed, it is possible that vaccinated people who get infected may easily remain asymptomatic or present with mild symptoms and thus go unnoticed. Vaccinated people could spread the virus even more insidiously, especially when high viral loads are confirmed. This is because during the COVID-19 mass vaccination campaign, adherence to social distancing by vaccinated people might be disregarded. Therefore, consistent adherence to public health safety measures such as the use of face masks, social distancing measures and practice of hand washing and other hygienic measures is essential. The appropriate use of personal protective equipment (i.e., surgical mask and filtering facepiece 2 in certain high-risk environments, such as crowded places, public transport and indoor workplaces like schools or hospitals, should also be encouraged [10,11]. In addition, occupational health safety practices including health surveillance, screening, testing and contact tracing activities should be promoted [12-14]. During the mass vaccination campaign, identifying the limited number of COVID-19 carriers, asymptomatic or symptomatic, who are responsible for a high proportion of cases (i.e., the ‘super spreaders’) is key for the success of the strategies against the virus [15]. Super-spreaders are people known to be individuals with a high viral load, but not necessarily with COVID-19-related complications. Viral shedding occurs rapidly among the super-spreaders and elimination of their viral load to zero level is delayed [16]. According to Cave, about 10% of super spreaders of SARS-CoV-2 may be responsible for up to 80% of confirmed COVID-19 cases [17]. Exposure to high viral loads may thus result in high-intensity infection, which exposes new cases to high viral loads. Thus, super spreaders generate new super spreaders [18]. Identification of super spreaders should be immediately undertaken through rigorous contact tracing activity, as the number of patients with severe COVID-19 complications declines. In the next few weeks, new SARS-CoV-2 strains and mutations may emerge. Genomic surveillance to detect new viral strain is therefore necessary. This will help to delay viral shedding as well as reduce the proportion of asymptomatics longer periods [19]. For this reason, testing of symptomatic patients and suspected individuals is vital. Self-testing with antigen tests might be an innovative strategy to promptly identify new COVID-19 cases [20]. SARS-CoV-2 has been shown to be consistently present in saliva. The reverse-transcription PCR of saliva specimens has some advantages over nasal and oropharyngeal swabs, such as cost–effectiveness and avoidance of contact with healthcare workers during specimen collection [21]. Workplace health surveillance should be mounted by local public health agencies in collaboration with occupational physicians to enable prompt testing of individuals. Furthermore, asymptomatic healthcare workers [20] and workers who work on infectious disease wards or COVID-19 isolation centers should maintain high levels of infection prevention and control practices. The general healthcare workers’ population should be encouraged to accept the COVID-19 vaccine. It is yet to be confirmed that available COVID-19 vaccines offer complete immunity against the Delta variant of SARS-CoV-2, thus herd immunity is unlikely until 100% people receive at least two doses of the COVID-19 vaccine [21]. For this reason, vaccinations should be encouraged across the populace and stated as a requirement for high-risk categories such as healthcare workers and fragile persons (aged >50 years, and those affected by comorbidities) who can put the healthcare system under immense pressure. During the ongoing mass vaccination campaign, there are currently insufficient data for efficacy, safety and effectiveness in children under 16 years of age for Pfizer and under 18 years for the Moderna vaccine. These therefore constitute important ethical concerns. Some cases of myocarditis and pericarditis have also been reported among young males following the administration of the second dose of mRNA vaccines (Pfizer-BioNTech and Moderna). However, the benefits (prevention of severe COVID-19 disease and associated hospitalizations, intensive care units’ admissions and deaths) outweigh the risks (including expected myocarditis after vaccination) in all populations for which vaccination is recommended [22]. Furthermore, published clinical trials do not report any long-term side effect following the administration of these vaccines for emergency use. Another issue concerns people who cannot get vaccinated for medical reasons and will likely remain without protection, especially if herd immunity cannot be attained. In conclusion, asymptomatic COVID-19 cases could be drivers of the COVID-19 pandemic, thus constituting a public health threat across the globe. Therefore, promoting the use of point-of-care testing and self testing to identify and quarantine asymptomatic people and healthcare workers with a high viral load is needed. While the mass vaccination campaign proceeds, consistent adherence to public health safety measures such as the use of face masks, social distancing measures and practice of hand washing and other hygienic measures is extremely important. Also, the appropriate use of personal protective equipment by healthcare workers and the implementation of health surveillance at workplace should be immediately undertaken. Finally, rigorous contact tracing represents a decisive step in the fight against the COVID-19 pandemic. For this cause, community healthcare workers and community stakeholders should be empowered as focal persons.
  18 in total

1.  The Role of Health Surveillance for the SARS-CoV-2 Risk Assessment in the Schools.

Authors:  Francesco Chirico
Journal:  J Occup Environ Med       Date:  2021-04-01       Impact factor: 2.162

2.  Impact of super-spreaders on COVID-19: systematic review.

Authors:  Ana Paula Schmitz Rambo; Laura Faustino Gonçalves; Ana Inês Gonzáles; Cassiano Ricardo Rech; Karina Mary de Paiva; Patrícia Haas
Journal:  Sao Paulo Med J       Date:  2021 Mar-Apr       Impact factor: 1.044

Review 3.  Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review.

Authors:  Daniel P Oran; Eric J Topol
Journal:  Ann Intern Med       Date:  2020-06-03       Impact factor: 25.391

4.  Do superspreaders generate new superspreaders? A hypothesis to explain the propagation pattern of COVID-19.

Authors:  Pablo M Beldomenico
Journal:  Int J Infect Dis       Date:  2020-05-11       Impact factor: 3.623

5.  Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies.

Authors:  Hanalise V Huff; Avantika Singh
Journal:  Clin Infect Dis       Date:  2020-12-17       Impact factor: 9.079

6.  COVID-19 Super-spreaders: Definitional Quandaries and Implications.

Authors:  Emma Cave
Journal:  Asian Bioeth Rev       Date:  2020-05-16

7.  Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis.

Authors:  Andreas Kronbichler; Daniela Kresse; Sojung Yoon; Keum Hwa Lee; Maria Effenberger; Jae Il Shin
Journal:  Int J Infect Dis       Date:  2020-06-17       Impact factor: 3.623

8.  Self-testing with antigen tests as a method for reduction SARS-CoV-2.

Authors:  Frank W Peacock; Tomasz Dzieciatkowski; Francesco Chirico; Lukasz Szarpak
Journal:  Am J Emerg Med       Date:  2021-05-06       Impact factor: 2.469

9.  Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.

Authors:  Catherine M Brown; Johanna Vostok; Hillary Johnson; Meagan Burns; Radhika Gharpure; Samira Sami; Rebecca T Sabo; Noemi Hall; Anne Foreman; Petra L Schubert; Glen R Gallagher; Timelia Fink; Lawrence C Madoff; Stacey B Gabriel; Bronwyn MacInnis; Daniel J Park; Katherine J Siddle; Vaira Harik; Deirdre Arvidson; Taylor Brock-Fisher; Molly Dunn; Amanda Kearns; A Scott Laney
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-08-06       Impact factor: 17.586

10.  Saliva as a Potential Diagnostic Specimen for COVID-19 Testing.

Authors:  Pandurangan Harikrishnan
Journal:  J Craniofac Surg       Date:  2020-09       Impact factor: 1.172

View more
  3 in total

1.  Second Wave of COVID-19 Pandemic in Argentinian Population: Vaccination Is Associated With a Decrease in Depressive Symptoms.

Authors:  Pedro Benedetti; Alejo Barbuzza; Franco Moscato; Victoria Reppucci; Celina Goyeneche; Cynthia Katche; Jorge H Medina; Haydee Viola; Fabricio Ballarini; Diego Moncada
Journal:  Front Psychiatry       Date:  2022-06-23       Impact factor: 5.435

2.  Risk Factors of Symptomatic COVID-19 in Samtse District, Bhutan.

Authors:  Karma Lhendup; Tsheten Tsheten; Tshewang Rinzin; Kinley Wangdi
Journal:  Front Public Health       Date:  2022-05-02

3.  Clinical epidemiological applicability of real-time polymerase chain reaction for COVID-19.

Authors:  Geehyuk Kim; Jun-Kyu Kang; Jungho Kim; Jiyoung Lee; Jin Gwack
Journal:  Osong Public Health Res Perspect       Date:  2022-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.